Tesamorelin 10mg + Ipamorelin 3mg from Novera Compounds is a fixed-ratio, lyophilized research peptide preparation designed for laboratory protocols that require both compounds within the same...
Tesamorelin 10mg + Ipamorelin 3mg from Novera Compounds is a fixed-ratio, lyophilized research peptide preparation designed for laboratory protocols that require both compounds within the same experimental material. The 10:3 formulation allows researchers to plan controlled in vitro studies while maintaining a defined relationship between the two peptide components. Intended strictly for in vitro research ONLY. NOT for human use, clinical application, or human consumption.
Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.
Batch number on every vial
Published Certificates of Analysis
Purity verified by third-party testing
Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.
The Tesamorelin 10mg + Ipamorelin 3mg vial from Novera Compounds is a lyophilized research peptide preparation, manufactured in the United States, that supplies both compounds in a single container at a fixed 10:3 ratio. Before researchers buy tesamorelin 10mg + ipamorelin 3mg for a research program, they should determine whether the study specifically requires a pre-combined GHRH analog and growth hormone secretagogue rather than separately sourced materials. This product is intended strictly for in vitro research ONLY. It is NOT approved for human use, clinical application, or human consumption.
A pre-combined formulation is most relevant when the experimental design requires tesamorelin and ipamorelin to be introduced together under the same study conditions. Using one defined research material can simplify preparation and documentation when simultaneous exposure is part of the protocol.
That convenience should not determine material selection on its own. If a study requires independent adjustment of either compound, separate research reagents may offer greater experimental flexibility. Choosing between a fixed-ratio blend and individual materials should therefore begin with the study question rather than with the packaging format. Researchers comparing this formulation with other research peptide blend products should consider whether the fixed 10:3 relationship is appropriate for the intended experimental design.
Tesamorelin is a GHRH analog whose FDA-labeled single-agent mechanism involves activation of the human GRF receptor and stimulation of GH release.[1] Ipamorelin has been studied separately as a growth hormone secretagogue, including in a Phase 2 trial for postoperative ileus that did not meet its primary endpoint.[2] These individual records provide scientific context, but they do not establish efficacy or clinical outcomes for the combined research formulation.
Qualified researchers looking to buy tesamorelin 10mg + ipamorelin 3mg blend for research can contact Med Supply Solutions for product and sourcing information.
A fixed-ratio research material gives laboratories control over total working concentration while preserving the manufactured relationship between the two peptide components. Changing the reconstitution volume alters the concentration of the prepared material, but it does not independently change the proportion of tesamorelin to ipamorelin.
For this reason, experimental planning should establish the required concentration, assay conditions, controls, and endpoints before preparation begins. There is no universal in vitro dosing schedule or reconstitution volume that applies across research protocols. Laboratories should select preparation conditions according to the requirements of the assay being performed.
This distinction is important when comparing a combined formulation with separately sourced peptides: the blend is useful when the fixed relationship is part of the experimental design, while individual reagents provide more flexibility when each compound must be adjusted independently.
In vitro research with the combined formulation may examine receptor-level and cellular responses associated with the growth hormone axis. Relevant experimental parameters can include GHRH-receptor and GHS-R1a activity, intracellular signaling responses, GH release from appropriate pituitary cell models, and selectivity assessments within the selected assay system.
The available human evidence belongs to the individual peptides rather than the blend. Tesamorelin has an FDA-approved single-agent indication in a defined patient population,[1] while ipamorelin has clinical exposure from a Phase 2 postoperative-ileus study that did not meet its primary efficacy endpoint.[2] Neither record establishes a therapeutic indication for the combined vial.
Whole-organism outcomes such as visceral adipose tissue changes, lean mass, recovery, insulin sensitivity, or glucose metabolism should therefore not be presented as direct outputs of an in vitro study using this material. When such outcomes appear in the literature, they should be understood within the animal or human studies from which they were derived.
Terms such as “growth-hormone axis peptide blend,” “advanced body composition stack,” or “tesa ipa blend” may be used descriptively, but they do not establish a validated human outcome.
Longer research programs should consider not only the material itself but also whether documentation remains consistent across successive orders. Certificate of analysis information, product identity records, lot numbers, and available purity documentation can help laboratories connect experimental records to the specific material received.
For groups that buy tesamorelin 10mg + ipamorelin 3mg wholesale, changes between lots should be recorded so that any variation in supplied material can be considered during later data review. Researchers purchasing online may also want to confirm documentation availability before material is incorporated into an active protocol.
For multi-stage or parallel studies, consistent recordkeeping across purchasing, receiving, preparation, and experimental use helps preserve traceability throughout the research period.
The blend is supplied in lyophilized form and requires preparation with an appropriate research-grade reconstitution medium before in vitro use. The volume selected should reflect the working concentration required by the laboratory's assay rather than a universal preparation schedule.
This workflow applies only to controlled laboratory preparation. It is not a human administration protocol. Tesamorelin 10mg + Ipamorelin 3mg is intended strictly for in vitro research and laboratory use only and is NOT approved for human use, clinical applications, or human consumption.
Compliance Notice: This product is intended strictly for in vitro research and laboratory use only. It is NOT approved for human use, clinical applications, or human consumption. Not for sale as a drug or pharmaceutical product. Licensed researchers only.
[1] U.S. Food and Drug Administration. "EGRIFTA (Tesamorelin for Injection) Prescribing Information." AccessData, 2010.
[2] Beck, David E et al. “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” International journal of colorectal disease vol. 29,12 (2014): 1527-34. doi:10.1007/s00384-014-2030-8
It may be appropriate when the study requires tesamorelin and ipamorelin to be evaluated together in a defined ratio. Studies requiring independent adjustment of either compound may be better suited to separate research materials.
Reconstitution changes the overall working concentration but does not independently alter the manufactured 10:3 relationship between the two peptide components.
Records may include product and lot identification, certificate of analysis information, preparation details, working concentration, storage conditions, and the protocol in which the material is used.
Cell- and receptor-level measurements can be investigated in appropriate in vitro models. Whole-organism outcomes such as visceral fat changes, lean mass, recovery, or metabolic effects come from separate in vivo literature and should not be attributed directly to this research formulation.
No human safety profile has been established specifically for the 10:3 combined research formulation. Available human information comes from studies of the individual peptides rather than this paired material.[1][2]
No. It is intended strictly for in vitro research ONLY. It is NOT approved for human use, clinical application, or human consumption.
Licensed researchers can contact Med Supply Solutions for product availability, documentation, and research sourcing guidance.
Subscribe for exclusive offers and updates on new arrivals